| Date | Title | Description | |
|---|---|---|---|
| 29 Apr 2021 | On business and financial situation | The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States. | Download |
| 12 Apr 2021 | On business and financial situation | The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 19 April and 25 April 2024 | Download |
| 19 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 12 April and 18 April 2024 | Download |
| 12 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 5 April and 11 April 2024 | Download |
| 05 Apr 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 28 March and 4 April 2024 | Download |
| 02 Apr 2024 | On business and financial situation | ROVI informs on the FDA’s approval of Risvan® as a treatment for schizophrenia | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
| 26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
| 15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
| 09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
| 08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |